JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on February 15, 2002
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
277/8/5944    most recent
M111394200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, T.
Right arrow Articles by Hsieh, T.-s.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hu, T.
Right arrow Articles by Hsieh, T.-s.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print December 7, 2001
J. Biol. Chem, 10.1074/jbc.M111394200
Submitted on November 29, 2001
Revised on December 7, 2001
Accepted on December 7, 2001

ATPase domain of eucaryotic DNA topoisomerase II: Inhibition of ATPase activity by the anti-cancer drug bisdioxopiperazine and ATP/ADP-induced dimerization

Tao Hu, Harvey Sage, and Tao-shih Hsieh

Department of Biochemistry, Duke University Medical Center, Durham, NC 27710

Corresponding Author: hsieh{at}biochem.duke.edu

We have prepared full-length Drosophila and human topoisomerase II, and truncation constructs containing the amino-terminal ATPase domain, and analyzed their biochemical properties. The ATPase activity of the truncation proteins, similar to that of the full-length proteins, is greatly stimulated by the presence of DNA. This activity of the truncation proteins is also sensitive to the inhibition by the drug bisdioxopiperazine, ICRF-193, albeit at a much lower level than the full-length protein. Therefore, bisdioxopiperazine can directly interact with the N-terminal ATPase domain, but the drug-enzyme interaction may involve other domains as well. The ATPase activity of the ATPase domain protein showed a quadratic dependence on enzyme concentration, suggesting that dimerization of the N-terminal domain is a rate-limiting step. Using both protein cross-linking and sedimentation equilibrium analysis, we showed that the ATPase domain exists as a monomer in the absence of cofactors, but can readily dimerize in the presence of a nonhydrolyzable analog of ATP, AMPPNP. More interestingly, both ATP and ADP can also promote protein dimerization. This result thus suggests that the protein clamp, mediated through the dimerization of ATPase domain, remains closed after ATP hydrolysis, and opens upon the dissociation of ADP.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
F. Mueller-Planitz and D. Herschlag
Coupling between ATP Binding and DNA Cleavage by DNA Topoisomerase II: A UNIFYING KINETIC AND STRUCTURAL MECHANISM
J. Biol. Chem., June 20, 2008; 283(25): 17463 - 17476.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Qin, L. Meng, C. Hu, W. Duan, Z. Zuo, L. Lin, X. Zhang, and J. Ding
Gambogic acid inhibits the catalytic activity of human topoisomerase II{alpha} by binding to its ATPase domain
Mol. Cancer Ther., September 1, 2007; 6(9): 2429 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. D. Smiley, T. R. L. Collins, G. G. Hammes, and T.-S. Hsieh
Single-molecule measurements of the opening and closing of the DNA gate by eukaryotic topoisomerase II
PNAS, March 20, 2007; 104(12): 4840 - 4845.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Zhu, M. Huang, F. Yang, Y. Chen, Z.-H. Miao, X.-H. Qian, Y.-F. Xu, Y.-X. Qin, H.-B. Luo, X. Shen, et al.
R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II
Mol. Cancer Ther., February 1, 2007; 6(2): 484 - 495.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C.-X. Hu, Z.-L. Zuo, B. Xiong, J.-G. Ma, M.-Y. Geng, L.-P. Lin, H.-L. Jiang, and J. Ding
Salvicine Functions as Novel Topoisomerase II Poison by Binding to ATP Pocket
Mol. Pharmacol., November 1, 2006; 70(5): 1593 - 1601.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Mueller-Planitz and D. Herschlag
Interdomain Communication in DNA Topoisomerase II: DNA BINDING AND ENZYME ACTIVATION
J. Biol. Chem., August 18, 2006; 281(33): 23395 - 23404.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Wei, A. J. Ruthenburg, S. K. Bechis, and G. L. Verdine
Nucleotide-dependent Domain Movement in the ATPase Domain of a Human Type IIA DNA Topoisomerase
J. Biol. Chem., November 4, 2005; 280(44): 37041 - 37047.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Vaughn, S. Huang, I. Wessel, T. K. Sorensen, T. Hsieh, L. H. Jensen, P. B. Jensen, M. Sehested, and J. L. Nitiss
Stability of the Topoisomerase II Closed Clamp Conformation May Influence DNA-stimulated ATP Hydrolysis
J. Biol. Chem., March 25, 2005; 280(12): 11920 - 11929.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. M. Immormino, D. E. Dollins, P. L. Shaffer, K. L. Soldano, M. A. Walker, and D. T. Gewirth
Ligand-induced Conformational Shift in the N-terminal Domain of GRP94, an Hsp90 Chaperone
J. Biol. Chem., October 29, 2004; 279(44): 46162 - 46171.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
N. Vilain, M. Tsai-Pflugfelder, A. Benoit, S. M. Gasser, and D. Leroy
Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase II{alpha}
Nucleic Acids Res., October 1, 2003; 31(19): 5714 - 5722.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Classen, S. Olland, and J. M. Berger
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187
PNAS, September 16, 2003; 100(19): 10629 - 10634.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Renodon-Corniere, T. K. Sorensen, P. B. Jensen, J. L. Nitiss, B. Sokilde, M. Sehested, and L. H. Jensen
Probing the Role of Linker Substituents in Bisdioxopiperazine Analogs for Activity against Wild-Type and Mutant Human Topoisomerase IIalpha
Mol. Pharmacol., May 1, 2003; 63(5): 1159 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
K. L. West, R. M. Turnbull, E. Willmore, J. H. Lakey, and C. A. Austin
Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase II{beta}: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability
Nucleic Acids Res., December 15, 2002; 30(24): 5416 - 5424.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.